uniQure N.V. Files 8-K Report
Ticker: QURE · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1590560
| Field | Detail |
|---|---|
| Company | Uniqure N.V. (QURE) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
uniQure filed a standard 8-K, mostly procedural stuff.
AI Summary
On June 3, 2024, uniQure N.V. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt, but it indicates a standard regulatory filing.
Why It Matters
This filing indicates uniQure N.V. is complying with regulatory requirements for reporting material information and financial updates to the SEC.
Risk Assessment
Risk Level: low — The filing is a routine regulatory disclosure and does not appear to contain any new material information that would immediately impact the company's risk profile.
Key Players & Entities
- uniQure N.V. (company) — Registrant
- June 3, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for uniQure N.V.?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is June 3, 2024.
What is uniQure N.V.'s principal executive office address?
The address is Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands.
What is uniQure N.V.'s telephone number?
The telephone number is +31 - 20-566-7394.
What is the SEC file number for uniQure N.V.?
The SEC file number is 001-36294.
Filing Stats: 552 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-06-03 07:18:51
Filing Documents
- qure-20240603x8k.htm (8-K) — 34KB
- qure-20240603xex99d1.htm (EX-99.1) — 23KB
- qure-20240603xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-008845.txt ( ) — 185KB
- qure-20240603.xsd (EX-101.SCH) — 3KB
- qure-20240603_lab.xml (EX-101.LAB) — 15KB
- qure-20240603_pre.xml (EX-101.PRE) — 10KB
- qure-20240603x8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 3, 2024, uniQure N.V. (the " Company ") issued a press release announcing that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy candidate AMT-130 for the treatment of Huntington's disease. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liability of such section, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of uniQure N.V. dated June 3, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. UNIQURE N.V. Date: June 3, 2024 By: /s/ Jeannette Potts JEANNETTE POTTS Chief Legal and Compliance Officer